NeuroSense reports positive results from its ALS trial
Drug Discovery World
MARCH 14, 2024
NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the previously reported results, PrimeC displayed a clinically meaningful effect on various aspects of patients’ quality of life, including ment
Let's personalize your content